Moderna, Inc.

Moderna, Inc.

MRNA

$248.61

Updated: 04/11/2026, 18:43:22

Market Cap
$99.34B
Sector
Healthcare
Industry
Biotechnology
Country
US

No historical data available

Company Profile

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

USD
NASDAQ
CEO: Stéphane Bancel
Employees: 4,700
https://www.modernatx.com
Asset Summaries
Latest generated summaries for MRNA

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
MRNA-10-k-fy2025.html2.6 MBtext/htmlENFiled 20/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 63 KPI observations

Revenue

$1.9B

FY 2025 · Reported

Net income

$-2.8B

FY 2025 · Reported

Gross margin

55.3%

FY 2025 · Calculated

Free cash flow

$-2.1B

FY 2025 · Calculated

R&D intensity

161.1%

FY 2025 · Calculated

Share repurchases

$0.0B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Commercial products: COVID and RSV vaccines, pipeline including seasonal flu and oncology

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Commercial success depends on physicians, patients, third-party payors and medical community acceptance

Market acceptance by physicians, patients, third-party payors and the medical community determines commercial success

95%
Source evidence
“The commercial success of our products depends on the degree of market acceptance by physicians, patients, third-party payors and others in the medical community”

Commercial products: COVID and RSV vaccines, pipeline including seasonal flu and oncology

COVID vaccines and RSV vaccine commercialized; pipeline includes seasonal flu, oncology, rare disease, and intismeran autogene individualized products

95%
Source evidence
“We compete with larger, well-established and experienced pharmaceutical companies for sales of our products, including against Pfizer and Sanofi for sales of our COVID vaccines and Pfizer and GSK for our RSV vaccine.”

Operations and dependencies

Two main Massachusetts campuses: MSC (Cambridge HQ) and MTC (Norwood)

Main campuses: Moderna Science Center (Cambridge, HQ, ~462,000 sq ft) and Moderna Technology Center (Norwood, ~722,000 sq ft, manufacturing/laboratory)

93%
Source evidence
“We have two main campuses in Massachusetts, our Moderna Science Center (MSC), located in Cambridge, which serves as our headquarters, and our Moderna Technology Center (MTC), located in Norwood.”

Positioning and strategy

FY2025 capex $192M, down $859M YoY

Purchases of property, plant and equipment of $192 million in 2025, an $859 million decrease vs 2024

95%
Source evidence
“purchases of property, plant and equipment of $192 million”

Named competitors: Pfizer, Sanofi, GSK

Pfizer and Sanofi compete for COVID vaccines; Pfizer and GSK compete for RSV vaccines

97%
Source evidence
“including against Pfizer and Sanofi for sales of our COVID vaccines and Pfizer and GSK for our RSV vaccine”

Multiple new product launches expected over next several years; selective R&D prioritization

Near-term strategy of launching multiple new products, growing infectious disease franchise, with a more selective and paced approach to R&D investment

90%
Source evidence
“our broad clinical success and post-pandemic commercial challenges have necessitated a more selective and paced approach to our research and development investment.”

Risks, financing, and outlook

November 2025 Credit Agreement — $1.5B term loan facility

Credit Agreement with $1.5B aggregate commitments; $600M initial term loan drawn as of Dec 31, 2025; $900M delayed draw; principal due in full at maturity in November 2030

98%
Source evidence
“In November 2025, we entered into a Credit Agreement providing for a term loan facility with aggregate commitments of $1.5 billion. As of December 31, 2025, we had drawn $600 million under the initial term loan.”

Liquidity sufficient for at least 12 months; continued negative operating cash flow expected

Cash, investments, product sales, and credit facility expected to fund operations through at least next 12 months; continued negative operating cash flows possible in upcoming periods

95%
Source evidence
“We believe that our cash, cash equivalents, and investments as of December 31, 2025, together with cash expected to be generated from product sales and available borrowings under our credit facility, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months”

Targets revenue growth in 2026 and cash breakeven via cost efficiency programs

Expects revenue growth in 2026 and aims to deliver cost efficiency and achieve targeted cash breakeven

90%
Source evidence
“our expectations regarding revenue growth in 2026; our ability to deliver cost efficiency across our business and to achieve targeted cash breakeven”

Non-cancelable open purchase orders ~$1.8B

~$1.8 billion cancelable open purchase orders with vendors for clinical operations/support and contract manufacturing as of Dec 31, 2025

95%
Source evidence
“At December 31, 2025, we had cancelable open purchase orders of approximately $1.8 billion, reflecting amounts associated with our significant vendor arrangements”

December 2024 acquisition of MTC campus for $385M

Acquired MTC campus (Norwood, ~722,000 sq ft) in December 2024 for $385M; ~$231M allocated to PP&E

95%
Source evidence
“In December 2024, we completed the acquisition of the MTC campus, including the underlying land and buildings, for a total purchase price of $385 million.”

FY2025 financing: $578M net proceeds from credit facility; investing provided $1.9B

Financing provided $593M in 2025 ($578M net from credit facility); investing provided $1.9B; retained earnings $7.2B at Dec 31, 2025

95%
Source evidence
“Net cash provided by financing activities in 2025 was $593 million, consisting of $578 million of net proceeds from our credit facility”

US regulatory uncertainty impacting vaccine demand (FDA, CDC, ACIP changes in 2025)

2025 changes at FDA, CDC and ACIP regarding policies, recommendations and eligibility affected and may continue to affect vaccine demand and costs

95%
Source evidence
“In 2025, changes at U.S. regulatory agencies impacted policies and priorities related to our industry. For example, changes in FDA regulatory policies, post-marketing safety monitoring, and evidentiary expectations, as well as CDC and Advisory Committee on Immunization Practices (ACIP) recommendations regarding eligibility, target populations, and vaccination practices, may have affected and may continue to affect demand for our vaccines.”

Net losses in 2025 and 2024; expects further losses

Incurred net losses in 2025 and 2024 and expects additional losses; may not achieve long-term sustainable profitability

95%
Source evidence
“We incurred net losses in 2025 and 2024, and expect to incur additional losses in the future; we have a limited history of recognizing revenue from product sales and may not achieve long-term sustainable profitability”

Exclusion from European COVID vaccine markets due to competitor's EC contract

Excluded from selling COVID vaccines in many European markets due to a competitor's European Commission contract that lapses year-end 2026

95%
Source evidence
“we have been excluded from selling our COVID vaccines in many European markets due to a competitor’s contract with the European Commission, which does not lapse until year-end 2026”

Continued COVID vaccine demand decline into 2025

COVID vaccine demand declined in 2023 and 2024 and the trend continued into 2025 amid a more competitive, commercially driven market

95%
Source evidence
“we experienced a decline in customer demand for our COVID vaccine in 2023 and 2024, and this trend has continued into 2025 as the market transitions to a more competitive and commercially driven environment”

FCPA/anti-bribery compliance exposure in pharma

Compliance with FCPA/UK Bribery Act is expensive and difficult; hospitals run by governments create foreign-official risk

95%
Source evidence
“We are also subject to extensive federal, state and foreign anti-bribery regulations, including the U.S. Foreign Corrupt Practices Act (FCPA), the UK Bribery Act and similar laws in other countries.”

Manufacturing, supply chain and infrastructure operational risks including internal and third-party facilities

Risks in manufacturing, release, shelf life, testing, storage, supply chain, shipping, and physical/digital infrastructure at own facilities and external providers

92%
Source evidence
“We or our third-party manufacturers may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping for any of our products”

Intense vaccine/pharma competition including pricing pressure and market practices reducing realized revenue

US private vaccine market practices (discounts, rebates, returns) may cause significantly lower realized revenues than list prices; competitors use bundling and larger networks

90%
Source evidence
“certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices”

RSV market challenges from more limited ACIP recommendations

Challenges in the RSV market partly due to advisory committee recommendations more limited than anticipated

90%
Source evidence
“Beyond COVID, we have experienced challenges in the RSV market, in part due to advisory committee recommendations that were more limited than anticipated.”

Payor consolidation and benefit design shifting costs to patients, increasing discounts/rebates

Consolidated large insurers and PBMs exert greater pricing pressure, significantly increasing discounts and rebates and limiting patient access

90%
Source evidence
“Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage.”

IP litigation and patent protection uncertainty; cybersecurity risk

IP disputes in pharma are costly with freedom-to-operate consequences; cybersecurity incidents could materially disrupt programs and manufacturing

88%
Source evidence
“Uncertainty over intellectual property in the pharmaceutical and biotechnology industry has been the source of litigation and other disputes, which is inherently costly and unpredictable and can have adverse financial and freedom-to-operate consequences”

Material exposure graph

COVID vaccine (Spikevax/mNEXSPIKE)
Demand Driver

Declining COVID vaccine demand in 2023-2025 drives lower revenue and inventory write-downs as market becomes seasonal and competitive.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“we experienced a decline in customer demand for our COVID vaccine in 2023 and 2024, and this trend has continued into 2025 as the market transitions to a more competitive and commercially driven environment”
FDA/CDC/ACIP vaccine policy
Revenue Exposure

2025 US regulatory and recommendation changes directly affect vaccine demand, approvals and costs.

Relevance 95·Dependency 80·Confidence 93
Source evidence
“may have affected and may continue to affect demand for our vaccines. Some of these changes, including new post-marketing commitments, have impacted and may in the future impact our costs.”
COVID vaccine (Spikevax/mNEXSPIKE)
Cost Driver

Seasonal market requires advance production planning ahead of each season, producing excess inventory and write-downs when demand deviates from forecast.

Relevance 90·Dependency 85·Confidence 93
Source evidence
“Forecasting demand for COVID vaccines requires advance production planning ahead of each season, including production of multiple COVID vaccine products, which resulted in excess inventory and capacity as actual demand differed from forecasted demand.”
Pfizer
Competitive Exposure

Pfizer competes directly with Moderna in both COVID and RSV vaccine markets.

Relevance 90·Dependency 70·Confidence 95
Source evidence
“including against Pfizer and Sanofi for sales of our COVID vaccines and Pfizer and GSK for our RSV vaccine”
Contract manufacturing and clinical operations vendors
Supplier Dependency

~$1.8B open purchase orders with non-terminable vendor agreements for clinical operations and contract manufacturing represent significant supplier commitments.

Relevance 85·Dependency 80·Confidence 93
Source evidence
“At December 31, 2025, we had cancelable open purchase orders of approximately $1.8 billion, reflecting amounts associated with our significant vendor arrangements, under such agreements for our clinical operations and support and contract manufacturing.”
Physicians, patients and third-party payors
Demand Driver

Market acceptance by physicians, patients, payors and the medical community drives product commercial success and reimbursement-dependent revenue.

Relevance 85·Dependency 80·Confidence 92
Source evidence
“Sales of pharmaceutical products depend on adequate coverage, pricing and reimbursement from third-party payors.”
Massachusetts campuses (Cambridge HQ; Norwood MTC)
Manufacturing Dependency

MTC in Norwood is a critical facility for manufacturing, laboratory, and office operations; acquired for $385M in December 2024.

Relevance 80·Dependency 75·Confidence 92
Source evidence
“The MTC has been a critical facility for our manufacturing, laboratory, and office operations.”
Raw materials (vaccine manufacturing)
Raw Material Dependency

Firm non-cancellable raw material purchase commitments generated losses when materials expire before anticipated consumption; accrued loss liability of $5M at Dec 31, 2025.

Relevance 75·Dependency 70·Confidence 90
Source evidence
“Losses on firm purchase commitments were primarily related to excess raw material purchase commitments that will expire before the anticipated consumption of those raw materials.”
Sanofi
Competitive Exposure

Sanofi competes with Moderna for COVID vaccine sales.

Relevance 75·Dependency 55·Confidence 95
Source evidence
“against Pfizer and Sanofi for sales of our COVID vaccines”
GSK
Competitive Exposure

GSK competes with Moderna in the RSV vaccine market entered with two larger incumbents.

Relevance 75·Dependency 55·Confidence 95
Source evidence
“Pfizer and GSK for our RSV vaccine”
Large insurers and pharmacy benefit managers
Customer Exposure

Payor/PBM consolidation increases required discounts and rebates and limits patient access, reducing realized revenue.

Relevance 70·Dependency 60·Confidence 88
Source evidence
“Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage.”
European COVID vaccine markets
Geopolitical Exposure

Exclusion from many European markets until a competitor's EC contract lapses year-end 2026 limits COVID vaccine revenue geography.

Relevance 70·Dependency 60·Confidence 90
Source evidence
“we have been excluded from selling our COVID vaccines in many European markets due to a competitor’s contract with the European Commission, which does not lapse until year-end 2026”
mRESVIA (RSV vaccine)
Revenue Exposure

mRESVIA (RSV vaccine) is part of commercial inventory; inventory on hand of $267M includes COVID and RSV vaccines.

Relevance 60·Dependency 55·Confidence 88
Source evidence
“we had inventory on hand of $267 million and $267 million, respectively, inclusive of inventory for our COVID and RSV vaccines”
Foreign Corrupt Practices Act
Legal Exposure

Pharma interactions with government-operated hospitals abroad make FCPA compliance costly and create enforcement/debarment risk.

Relevance 60·Dependency 40·Confidence 90
Source evidence
“the FCPA presents particular challenges to the pharmaceutical industry because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.”
Interest rates
Cost Driver

Credit Agreement borrowings bear variable interest at Term SOFR or base rate plus margin, exposing financing costs to rate changes.

Relevance 55·Dependency 50·Confidence 90
Source evidence
“Borrowings under the Credit Agreement bear interest at a variable rate based on Term SOFR or a base”
Full company information
Latest profile, trading, valuation, and identifier data stored for MRNA.
Share price
$248.61
Market cap
$99.34B
Exchange
NASDAQ
Currency
USD
CEO
Stéphane Bancel
Employees
4,700
IPO date
07/12/2018
Beta
0.899
Last dividend
$0.00
Day range
$230.21 – $253.72
52-week range
$22.28 – $254.48
1-day performance
8.83%
1-year performance
1015.85%
Current drawdown (1Y)
-2.31%
CIK
0001682852
CUSIP
60770K107
ISIN
US60770K1079
Created
07/12/2025, 05:19:32
Last update
04/11/2026, 18:43:22

Track Moderna, Inc. with an AI analyst

See which prediction-market events move MRNA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to MRNA from your Railway `news_articles` table.

Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 19:32:09

Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™”

GlobeNewsWire • STOCK • 02/06/2026, 18:34:00

MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus

Zacks Investment Research • STOCK • 02/06/2026, 14:01:20

Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript

Seeking Alpha • STOCK • 02/06/2026, 03:04:05

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

Reuters • STOCK • 01/06/2026, 07:37:58

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

Accesswire • STOCK • 01/06/2026, 07:00:00

Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Seeking Alpha • STOCK • 30/05/2026, 05:54:06

Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now

24/7 Wall Street • STOCK • 21/05/2026, 11:36:43

Moderna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 19/05/2026, 14:20:46

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 12/05/2026, 18:50:51

Moderna's AI Could Get a Hantavirus Vaccine Here Faster

PYMNTS • STOCK • 12/05/2026, 15:25:37

Moderna Says It's Researching a Hantavirus Vaccine. The Drugmaker's Stock Is Surging.

Investopedia • STOCK • 11/05/2026, 22:19:50